Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Jonsson Comprehensive Cancer Center
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center Identifier:
First received: June 27, 2006
Last updated: July 5, 2016
Last verified: July 2016
During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues. Optical Coherence Tomography imaging of intraocular tumors may lead to improved diagnosis and monitoring of tumors within the eye.

Ocular Melanoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Estimated Enrollment: 800
Study Start Date: March 2004
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who meet the following Eligibility Criteria

Inclusion Criteria:

  • Adults (18 years or older) with:

    • choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or greater than or equal to 1.25 mm in apical height or:
    • choroidal melanoma located in the posterior pole (4mm or less from the center of fovea or the border of the optic nerve head)

Exclusion Criteria:

  • Ocular media opacity in the tumor eye that prevents adequate functional testing or imaging and prior or concurrent retinal or choroidal disease in the tumor eye that prevents adequate functional testing or imaging
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346372

Contact: Tara A McCannel, MD, PhD (310) 206-7484
Contact: Brangel Rangel 310 794-9962

United States, California
Jules Stein Eye Institute Recruiting
Los Angeles, California, United States, 90095
Contact: Brenda Rangel    310-794-9962   
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Principal Investigator: Bradley R Straatsma, MD, JD Jules Stein Eye Institute, UCLA
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00346372     History of Changes
Other Study ID Numbers: UCLA IRB#03-11-052 
Study First Received: June 27, 2006
Last Updated: July 5, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Jonsson Comprehensive Cancer Center:
Ocular Melanoma
Optical Coherence Tomography
Eye Tumor
Choroidal Melanoma
Uveal Melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on October 27, 2016